258 results on '"Coyle, Thomas"'
Search Results
252. STRESS DISTRIBUTION OF MONOLITHIC AND VENEERED THREE-UNIT ZIRCONIA FDPS: A FINITE ELEMENT ANALYSIS.
- Author
-
Alsarani MM, El-Mowaf OY, Coyle TW, Rizkalla A, and Fava J
- Subjects
- Denture Design, Ceramics chemistry, Humans, Dental Porcelain chemistry, Dental Restoration Failure, Stress, Mechanical, Dental Materials chemistry, Zirconium chemistry, Finite Element Analysis, Dental Veneers, Denture, Partial, Fixed, Dental Stress Analysis, Materials Testing, Computer-Aided Design
- Abstract
Purpose: To evaluate the effect of restoration design on fracture resistance and stress distribu0on of veneered and monolithic three-unit zirconia fixed partial dentures (FDPs) using finite element analysis (FEA)., Materials and Methods: Identical epoxy resin replicas of mandibular second premolars and second molars (to serve as abutments for the three-unit bridges) were divided into four groups (n = 10): monolithic zirconia (MZ) restorations; conventional layering veneering technique (ZL); heat pressed-on technique (ZP); or CAD/CAM lithium-disilicate glass-ceramics (CAD-on). Specimens were subjected to compressive cyclic loading on the mesio-buccal cusp of the pontic (load range 50 to 600 N; aqueous environment; 500,000 cycles) in a universal testing machine. Data were statistically analyzed at 5% significance level with Fisher exact test and Kaplan-Meier survival analysis. 3D models were constructed in accordance with experimental groups. The stress distribution in each model was analyzed and evaluated according to the location and magnitude of the maximum principal stresses (MPSs) using ANSYS so\ware., Results: Specimens from ZL and ZP groups failed at different stages of the 500,000 cycles fatigue, while CAD-on and MZ restorations survived the fatigue test. Statistically, there was a significant difference between the groups (P < .001). The MPS were located under the mesial connector in both monolithic and bilayered three-unit zirconia FDPs. These stresses were found to be higher in monolithic geometries compared to bilayered zirconia FDPs., Conclusions: Monolithic threeunit zirconia and CAD-on zirconia frameworks resulted in superior fracture resistance. Restora0on design significantly affected the stress distribu0on of three-unit zirconia FDPs.
- Published
- 2024
- Full Text
- View/download PDF
253. Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components.
- Author
-
Wheeler AP, Snyder EL, Refaai M, Cohn CS, Poisson J, Fontaine M, Sehl M, Nooka AK, Uhl L, Spinella PC, Fenelus M, Liles D, Coyle T, Becker J, Jeng M, Gehrie EA, Spencer BR, Young P, Johnson A, O'Brien JJ, Schiller GJ, Roback JD, Malynn E, Jackups R, Avecilla ST, Liu K, Bentow S, Varrone J, Benjamin RJ, and Corash LM
- Subjects
- Humans, Female, Middle Aged, Male, Aged, Acute Lung Injury etiology, Blood Platelets, Prospective Studies, Adult, Thrombocytopenia etiology, Hematologic Diseases therapy, Platelet Transfusion adverse effects
- Abstract
Abstract: Patients treated with antineoplastic therapy often develop thrombocytopenia requiring platelet transfusion, which has potential to exacerbate pulmonary injury. This study tested the hypothesis that amotosalen-UVA pathogen-reduced platelet components (PRPCs) do not potentiate pulmonary dysfunction compared with conventional platelet components (CPCs). A prospective, multicenter, open-label, sequential cohort study evaluated the incidence of treatment-emergent assisted mechanical ventilation initiated for pulmonary dysfunction (TEAMV-PD). The first cohort received CPC. After the CPC cohort, each site enrolled a second cohort transfused with PRPC. Other outcomes included clinically significant pulmonary adverse events (CSPAE) and the incidence of treatment-emergent acute respiratory distress syndrome (TEARDS) diagnosed by blinded expert adjudication. The incidence of TEAMV-PD in all patients (1068 PRPC and 1223 CPC) was less for PRPC (1.7 %) than CPC (3.1%) with a treatment difference of -1.5% (95% confidence interval [CI], -2.7 to -0.2). In patients requiring ≥2 PCs, the incidence of TEAMV-PD was reduced for PRPC recipients compared with CPC recipients (treatment difference, -2.4%; 95% CI, -4.2 to -0.6). CSPAE increased with increasing PC exposure but were not significantly different between the cohorts. For patients receiving ≥2 platelet transfusions, TEARDS occurred in 1.3% PRPC and 2.6% CPC recipients (P = .086). Bayesian analysis demonstrated PRPC may be superior in reducing TEAMV-PD and TEARDS for platelet transfusion recipients compared with CPC recipients, with 99.2% and 88.8% probability, respectively. In this study, PRPC compared with CPC demonstrated high probability of reduced severe pulmonary injury requiring assisted mechanical ventilation in patients with hematology disorders dependent on platelet transfusion. This trial was registered at www.ClinicalTrials.gov as #NCT02549222., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
254. Altered Extracellular Vesicle MicroRNA Expression in Ischemic Stroke and Small Vessel Disease.
- Author
-
van Kralingen JC, McFall A, Ord ENJ, Coyle TF, Bissett M, McClure JD, McCabe C, Macrae IM, Dawson J, and Work LM
- Subjects
- Animals, Disease Models, Animal, Male, Rats, Inbred SHR, Rats, Inbred WKY, Stroke complications, Brain Ischemia blood, Cerebral Small Vessel Diseases blood, Extracellular Vesicles metabolism, MicroRNAs blood, Stroke blood
- Abstract
Active transport of microRNAs (miRNA) in extracellular vesicles (EV) occurs in disease. Circulating EV-packaged miRNAs in the serum of stroke patients were compared to stroke mimics with matched cardio- and cerebrovascular risk factors, with corroboration of results in a pre-clinical model. An unbiased miRNA microarray was performed in stroke vs. stroke mimic patients (n = 39). Results were validated (n = 173 patients) by real-time quantitative polymerase chain reaction. miRNA expression was quantified in total serum/EV (n = 5-7) of naïve adult spontaneously hypertensive stroke-prone rats (SHRSP), their normotensive reference strain (Wistar Kyoto, WKY) and in circulating EV (n = 3), peri-infarct brain (n = 6), or EV derived from this region (n = 3) in SHRSP following transient middle cerebral artery occlusion (tMCAO). Circulating EV concentration did not differ between stroke and stroke mimic patients. The microarray identified many altered EV-packaged miRNAs: levels of miRNA-17-5p, -20b-5p and -93-5p (miRNA-17 family members) and miRNA-27b-3p were significantly (p ≤ 0.05) increased in stroke vs. stroke mimic patients. Patients with small vessel disease (SVD) consistently had the highest miRNA levels. Circulating EV concentration was unaltered between naïve SHRSP and WKY but levels of miRNA-17-5p and -93-5p were significantly increased in SHRSP. tMCAO in SHRSP did not further alter circulating EV miRNA-17 family member expression and nor did it change total miRNA-17 family levels in peri-infarct brain tissue or in EV isolated from this region at 24 h post-tMCAO. Changes in EV packaged miRNA expression was validated in patients with stroke, particularly those with SVD and corroborated pre-clinically. Together, altered circulating EV levels of miRNA-17 family members may reflect the chronic sequelae underlying cerebrovascular SVD rather than the acute ischemic stroke itself.
- Published
- 2019
- Full Text
- View/download PDF
255. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.
- Author
-
Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni DE, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, Hebda N, Mitchell KM, Rosati KL, and Safran H
- Subjects
- Academic Medical Centers, Adult, Aged, Aged, 80 and over, Brain Neoplasms pathology, DNA Methylation, Disease-Free Survival, Dose-Response Relationship, Drug, Dose-Response Relationship, Radiation, Female, Follow-Up Studies, Glioblastoma pathology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Invasiveness pathology, Neoplasm Staging, Paclitaxel administration & dosage, Polyglutamic Acid administration & dosage, Radiotherapy, Adjuvant, Single-Blind Method, Survival Analysis, Treatment Outcome, United States, Brain Neoplasms mortality, Brain Neoplasms therapy, DNA Modification Methylases metabolism, DNA Repair Enzymes metabolism, Glioblastoma mortality, Glioblastoma therapy, Paclitaxel analogs & derivatives, Polyglutamic Acid analogs & derivatives, Tumor Suppressor Proteins metabolism
- Abstract
Purpose: Efficacy signals but substantial myelosuppression were demonstrated in a single arm phase II study of paclitaxel poliglumex (PPX) in combination with temozolomide (TMZ) and radiation therapy (RT) for first-line treatment of glioblastoma. The objective of this randomized phase II trial was to assess the efficacy and safety of single-agent PPX with RT (PPX/RT) versus TMZ with RT (TMZ/RT) for glioblastoma without O-methylguanine-DNA methyltransferase (MGMT) methylation., Materials and Methods: Patients with glioblastoma with unmethylated MGMT without prior chemotherapy or RT were eligible. Patients were randomly assigned 2:1 to PPX, 50 mg/m/wk for 6 weeks, or standard TMZ, with concurrent 60.0 Gy RT. One month after completion of chemoradiation all patients received standard maintenance TMZ. The primary endpoint was progression-free survival (PFS)., Results: Of the 164 patients enrolled, 86 were MGMT unmethylated. Of these, 63 patients were randomized (42 to PPX/RT and 21 to TMZ/RT). Fifty-nine patients could be analyzed. The median PFS was 9 months in the PPX/RT group and 9.5 months in the TMZ/RT group (hazard ratio in the PPX/RT group, 1.10; 95% confidence interval, 0.79-2.08; P=0.75). Median overall survival was 16 versus 14.8 months for PPX/RT and TMZ/RT groups, respectively (hazard ratio, 1.44; 95% confidence interval, 0.75-2.77; P=0.27). In the PPX and TMZ groups 44% versus 22% of patients, respectively, experienced one or more grade 3 or higher toxicities during chemoradiation., Conclusions: PPX/RT did not improve PFS or overall survival. This study provides an effective trial design for screening RT sensitizers in glioblastoma.
- Published
- 2018
- Full Text
- View/download PDF
256. Association of White Matter With Core Cognitive Deficits in Patients With Schizophrenia.
- Author
-
Kochunov P, Coyle TR, Rowland LM, Jahanshad N, Thompson PM, Kelly S, Du X, Sampath H, Bruce H, Chiappelli J, Ryan M, Fisseha F, Savransky A, Adhikari B, Chen S, Paciga SA, Whelan CD, Xie Z, Hyde CL, Chen X, Schubert CR, O'Donnell P, and Hong LE
- Subjects
- Adult, Anisotropy, Case-Control Studies, Cognition Disorders complications, Cross-Sectional Studies, Diffusion Tensor Imaging, Female, Humans, Male, Memory, Short-Term, Neuroimaging, Neuropsychological Tests, Schizophrenia complications, Young Adult, Cognition Disorders physiopathology, Schizophrenia physiopathology, Schizophrenic Psychology, White Matter physiopathology
- Abstract
Importance: Efforts to remediate the multiple cognitive function impairments in schizophrenia should consider white matter as one of the underlying neural mechanisms., Objective: To determine whether altered structural brain connectivity is responsible for 2 of the core cognitive deficits in schizophrenia- reduced information processing speed and impaired working memory., Design, Setting, and Participants: This cross-sectional study design took place in outpatient clinics from August 1, 2004, to August 31, 2015. Participants included 166 patients with schizophrenia and 213 healthy control individuals. These participants were from 3 independent cohorts, each of which had its own healthy control group. No participant had current or past neurological conditions or major medical conditions. Patients were diagnosed with either schizophrenia or schizoaffective disorder as defined by the DSM-IV. Controls had no Axis I psychiatric disorder., Main Outcomes and Measures: Mediation analyses and structural equation modeling were used to analyze the associations among processing speed, working memory, and white matter microstructures. Whole-brain and regional diffusion tensor imaging fractional anisotropy were used to measure white matter microstructures., Results: Of the study participants, the 166 patients with schizophrenia had a mean (SD) age of 38.2 (13.3) years and the 213 healthy controls had a mean (SD) age of 39.2 (14.0) years. There were significantly more male patients than controls in each of the 3 cohorts (117 [70%] vs 91 [43%]), but there were no significant differences in sex composition among the 3 cohorts. Patients had significantly reduced processing speed (Cohen d = 1.24; P = 6.91 × 10-30) and working memory deficits (Cohen d = 0.83; P = 1.10 × 10-14) as well as a significant whole-brain fractional anisotropy deficit (Cohen d = 0.63; P = 2.20 × 10-9). In schizophrenia, working memory deficit was mostly accounted for by processing speed deficit, but this deficit remained when accounting for working memory (Cohen d = 0.89; P = 2.21 × 10-17). Mediation analyses showed a significant association pathway from fractional anisotropy to processing speed to working memory (P = 5.01 × 10-7). The strength of this brain-to-cognition pathway in different white matter tracts was strongly associated with the severity of schizophrenia-associated fractional anisotropy deficits in the corresponding white matter tracts as determined by a meta-analysis (r = 0.85-0.94; all P < .001). The same pattern was observed in patients and controls either jointly or independently., Conclusions and Relevance: Study findings suggest that (1) processing speed contributes to the association between white matter microstructure and working memory in schizophrenia and (2) white matter impairment in schizophrenia is regional tract-specific, particularly in tracts normally supporting processing speed performance.
- Published
- 2017
- Full Text
- View/download PDF
257. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.
- Author
-
Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, and Reardon D
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Brain Neoplasms genetics, Disease-Free Survival, Female, Fibronectins adverse effects, Glioblastoma genetics, Glucuronosyltransferase genetics, Humans, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local genetics, Peptide Fragments adverse effects, Polymorphism, Genetic, Protein Kinase Inhibitors adverse effects, Antineoplastic Agents therapeutic use, Brain Neoplasms drug therapy, Fibronectins therapeutic use, Glioblastoma drug therapy, Peptide Fragments therapeutic use, Protein Kinase Inhibitors therapeutic use, Vascular Endothelial Growth Factor Receptor-2 antagonists & inhibitors
- Abstract
VEGF signaling through VEGFR-2 is the major factor in glioblastoma angiogenesis. CT-322, a pegylated protein engineered from the 10th type III human fibronectin domain, binds the VEGFR-2 extracellular domain with high specificity and affinity to block VEGF-induced VEGFR-2 signaling. This study evaluated CT-322 in an open-label run-in/phase 2 setting to assess its efficacy and safety in recurrent glioblastoma. Eligible patients had 1st, 2nd or 3rd recurrence of glioblastoma with measurable tumor on MRI and no prior anti-angiogenic therapy. The initial CT-322 dose was 1 mg/kg IV weekly, with plans to escalate subsequent patients to 2 mg/kg weekly if tolerated; within each CT-322 dose cohort, patients were randomized to ±irinotecan IV semiweekly. The primary endpoint was 6-month progression-free survival (PFS-6). Sixty-three patients with a median age of 56 were treated, the majority at first recurrence. One-third experienced serious adverse events, of which four were at least possibly related to study treatment (two intracranial hemorrhages and two infusion reactions). Twenty-nine percent of subjects developed treatment-emergent hypertension. The PFS-6 rate in the CT-322 monotherapy groups was 18.6 and 0.0 % in the 1 and 2 mg/kg treatment groups, respectively; results from the 2 mg/kg group indicated that the null hypothesis that PFS-6 ≤12 % could not be rejected. The study was terminated prior to reaching the planned enrollment for all treatment groups because data from the completed CT-322 2 mg/kg monotherapy treatment arm revealed insufficient efficacy. Despite biological activity and a tolerable side effect profile, CT-322 failed to meet the prespecified threshold for efficacy in recurrent glioblastoma.
- Published
- 2015
- Full Text
- View/download PDF
258. Processing speed mediates the development of general intelligence (g) in adolescence.
- Author
-
Coyle TR, Pillow DR, Snyder AC, and Kochunov P
- Subjects
- Adolescent, Age Factors, Cognition physiology, Female, Humans, Longitudinal Studies, Male, Neuropsychological Tests statistics & numerical data, Adolescent Development physiology, Intelligence physiology, Mental Processes physiology, Reaction Time physiology
- Abstract
In the research reported here, we examined whether processing speed mediates the development of general intelligence (g) in adolescence. Using the Armed Services Vocational Aptitude Battery, a battery of 12 diverse cognitive tests, we assessed processing speed and g in a large sample of 13- to 17-year-olds obtained from the National Longitudinal Survey of Youth (N = 6,969). The direct effect of age on g was small compared with the total effect of age on g, which was almost fully mediated through speed. The results suggest that increases in g in adolescence can be attributed to increases in mental speed.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.